Quantitative integration of pharmacokinetics/pharmacodynamics and disease progression modeling in pharmacometrics: A systems approach

Abstract

Quantitative data for comprehending the drug exposure-response connection is provided by the pharmacometric integration of the pharmacokinetics and pharmacodynamics (PK-PD) model. In addition to helping to understand important variables or mechanisms foundational drug actions, appropriate PK-PD models can predict potential drug impacts following various dose regimens toward dosage improvement. These models can determine many kinds of dose or concentration response connections, as well as complicated illness patterns as they relate to a specific dosage of drug. Conducting clinical trials has been problematic due to the inability to prove medication safety and efficacy, which has resulted in several clinical trial failures. It is disheartening that despite a drug's successful introduction into the pharmaceutical industry, a very high percentage of non-responders or toxic responders still exist because of fundamental disparities between the research cohort and population characteristics. This indicates that there is potential for improvement and that a significant quantity of information on the medication was overlooked during clinical testing. As a result, pharmacometrics is becoming a more useful tool in the pharmaceutical industry, regulatory bodies, academic research, and patient care to improve decision-making. Pharmacometrics explains the connections between medications, illnesses, and patients using numerical models. This study also emphasizes its uses and advantages at every step of a drug's life cycle, from creation to applied pharmacotherapy, and how usage contributes to slowing the advancement of certain illnesses.